Endothelial Jagged1 promotes solid tumor growth through both pro-angiogenic and angiocrine functions

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24404-24423

  Pedrosa, Ana Rita ^a   Trindade, Alexandre ^a,b   Carvalho, Catarina ^a   Graça, José ^a   Carvalho, Sandra ^a   Peleteiro, Maria C ^a   Adams, Ralf H ^c,d   Duarte, António ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^c MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Angiocrine; Jagged1; Notch; TRAMP; Tumor angiogenesis

Indexed keywords

HEY1 PROTEIN; JAGGED1; NOTCH3 RECEPTOR; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; CALCIUM BINDING PROTEIN; JAG1 PROTEIN, MOUSE; LIGAND; MEMBRANE PROTEIN; NOTCH RECEPTOR; PROTEIN JAGGED 1; SERRATE JAGGED PROTEIN; SIGNAL PEPTIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GAIN OF FUNCTION MUTATION; LEWIS CARCINOMA; LOSS OF FUNCTION MUTATION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; DISEASE COURSE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HYPOXIA; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; METABOLISM; MUTATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PERFUSION; PHENOTYPE; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CALCIUM-BINDING PROTEINS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JAGGED-1 PROTEIN; LIGANDS; MALE; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION; PHENOTYPE; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; SERRATE-JAGGED PROTEINS; SIGNAL TRANSDUCTION;

EID: 84943408033     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4380     Document Type: Article

References (49)

1. Folkman J. Tumor angiogenesis:therapeutic implications. The New England journal of medicine. 1971;285:1182-1186.
2. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
3. Schweisguth F. Regulation of notch signaling activity. Current biology :CB. 2004;14:R129-138.
4. Duarte A, Hirashima M, Benedito R, Trindade A, Diniz P, Bekman E, Costa L, Henrique D and Rossant J. Dosagesensitive requirement for mouse Dll4 in artery development. 2004;18:2474-2478.
5. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD and Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006; 444:1032-1037.
6. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang W-C, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo J-AS, de Sauvage F, Plowman G, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006; 444:1083-1087.
7. Sainson RCA and Harris AL. Anti-Dll4 therapy:can we block tumour growth by increasing angiogenesis? Trends in Molecular Medicine. 2007;13:389-395.
8. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, Gendron-Maguire M, Rand EB, Weinmaster G and Gridley T. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Human molecular genetics. 1999;8:723-730.
9. Li L, Miano JM, Cserjesi P and Olson EN. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis. Circulation Research. 1996;78:188-195.
10. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M and Adams RH. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell. 2009; 137:1124-1135.
11. Pedrosa AR, Trindade A, Fernandes AC, Carvalho C, Gigante J, Tavares AT, Dieguez-Hurtado R, Yagita H, Adams RH and Duarte A. Endothelial JAGGED1 antagonizes dll4 regulation of endothelial branching and promotes vascular maturation downstream of dll4/notch1. Arterioscler Thromb Vasc Biol. 2015;35:1134-1146.
12. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J and Wang CY. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8:13-23.
13. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ and Kitajewski J. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Research. 2008;68:4727-4735.
14. Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher DW, Shido K, Rafii A, Scandura JM and Rafii S. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. Cancer Cell. 2014;25:350-365.
15. Kangsamaksin T, Murtomaki A, Kofler NM, Cuervo H, Chaudhri RA, Tattersall IW, Rosenstiel PE, Shawber CJ and Kitajewski J. NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. Cancer Discov. 2015;5:182-197.
16. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM. Prostate cancer in a transgenic mouse. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:3439-3443.
17. Gingrich JR, Barrios RJ, Foster BA and Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 1999; 2:70-75.
18. Kaplan-Lefko PJ, Chen T-M, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA and Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. The Prostate. 2003;55:219-237.
19. Su SL, Huang IP, Fair WR, Powell CT and Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA:ratio of expression as a potential measurement of progression. Cancer Res. 1995;55:1441-1443.
20. Winkler EA, Bell RD and Zlokovic BV. Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener. 2010;5:32.
21. Vikkula M, Boon LM, Carraway KL, 3rd, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB and Olsen BR. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996; 87:1181-1190.
22. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
23. Zavadil J, Cermak L, Soto-Nieves N and Böttinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. The EMBO Journal. 2004;23:1155-1165.
24. Liu H, Kennard S and Lilly B. NOTCH3 expression is induced in mural cells through an autoregulatory loop that requires endothelial-expressed JAGGED1. Circulation Research. 2009;104:466-475.
25. Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM and Schaeffer EM. Gene expression pathways of high grade localized prostate cancer. The Prostate. 2011.
26. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine. 2004;350:2335-2342.
27. Meadows KL and Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med. 2012;2.
28. Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
29. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW and Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Research. 2001;61:2736-2743.
30. Thomas M and Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12:125-137.
31. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH and Epstein JA. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proceedings of the National Academy of Sciences. 2008;105:1955-1959.
32. Manderfield LJ, High FA, Engleka KA, Liu F, Li L, Rentschler S and Epstein JA. Notch activation of Jagged1 contributes to the assembly of the arterial wall. Circulation. 2012;125:314-323.
33. Abramsson A, Berlin O, Papayan H, Paulin D, Shani M and Betsholtz C. Analysis of mural cell recruitment to tumor vessels. Circulation. 2002;105:112-117.
34. Raza A, Franklin MJ and Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. American Journal of Hematology. 2010.
35. Zhong H, Semenza GL, Simons JW and De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev. 2004; 28:88-93.
36. Higgins LH, Withers HG, Garbens A, Love HD, Magnoni L, Hayward SW and Moyes CD. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta. 2009;1787:1433-1443.
37. Costello LC and Franklin RB. 'Why do tumour cells glycolyse?':from glycolysis through citrate to lipogenesis. Mol Cell Biochem. 2005;280:1-8.
38. Pear WS and Simon MC. Lasting longer without oxygen: The influence of hypoxia on Notch signaling. Cancer Cell. 2005;8:435-437.
39. Diez H, Fischer A, Winkler A, Hu C-J, Hatzopoulos AK, Breier G and Gessler M. Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Experimental Cell Research. 2007;313:1-9.
40. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I and Karsan A. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med. 2007;204:2935-2948.
41. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y and Sarkar FH. Down-regulation of Jagged-1 induces cell growth inhibition and S phase arrest in prostate cancer cells. Int J Cancer. 2006;119:2071-2077.
42. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I, Maru DM, Hawke DH, Rak J, Mani SA, Zweidler-McKay P and Ellis LM. Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1. Cancer Cell. 2013;23:171-185.
43. Yan M, Callahan CA, Beyer JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K and Plowman GD. Chronic DLL4 blockade induces vascular neoplasms. Nature. 2010; 463:E6-7.
44. Smith DC, Eisenberg P, Stagg R, Manikhas G, Pavlovskiy A, Sikic B, Kapoun A and Benner SE. A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors. Ejc Suppl. 2010;8:73-73.
45. Kiernan AE, Xu J and Gridley T. The Notch ligand JAG1 is required for sensory progenitor development in the mammalian inner ear. PLoS Genetics. 2006;2:e4.
46. Monvoisin A, Alva JA, Hofmann JJ, Zovein AC, Lane TF and Iruela-Arispe ML. VE-cadherin-CreERT2 transgenic mouse:a model for inducible recombination in the endothelium. Developmental dynamics :an official publication of the American Association of Anatomists. 2006;235:3413-3422.
47. Bertram JS and Janik P. Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett. 1980;11:63-73.
48. Trindade A, Kumar SR, Scehnet JS, Lopes-da-Costa L, Becker J, Jiang W, Liu R, Gill PS and Duarte A. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008;112:1720-1729.
49. Crisan M, Corselli M, Chen WC and Peault B. Perivascular cells for regenerative medicine. J Cell Mol Med. 2012; 16:2851-2860.